Category: 3. Business

  • Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange :: Datavault AI Inc. (DVLT)

    Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange :: Datavault AI Inc. (DVLT)





    PHILADELPHIA, PA / ACCESS Newswire / February 20, 2026 / Datavault AI Inc. (NASDAQ:DVLT) (“Datavault AI” or the “Company”), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies announced today the anticipated launch of the Josh Gibson Stablecoin and dedicated Josh Gibson Name, Image, and Likeness (NIL) strategies for its forthcoming sports and entertainment focused NIL digital asset exchange. This initiative builds directly on Major League Baseball’s (MLB’s) historic integration of Negro Leagues (1920-1948) statistics into the official major league record and celebrates Black History Month by honoring the legacy of baseball icon Josh Gibson.

    As outlined in the MLB’s May 2024 press release, the statistics of the Negro Leagues have officially entered the major league record, recognizing the achievements of thousands of black players previously excluded from MLB. Josh Gibson, widely regarded as one of the greatest catchers and hitters in baseball history, now holds multiple all-time MLB records, including career batting average (.372), slugging percentage (.718), and on-base plus slugging (OPS 1.177), as well as several single-season marks. These updates affirm Gibson’s status among the game’s all-time greats.

    Leveraging Datavault AI’s patented Information Data Exchange® (IDE), Data Vault®, DataScore®, and DataValue® AI technologies, the Josh Gibson Stablecoin will build on the Company’s established stablecoin frameworks, including its patented Data Vault platform in alignment with emerging regulations such as the GENIUS Act and Stable Coin Act. The Josh Gibson Stablecoin will be a digital asset designed to support legacy preservation, fan engagement, and tokenized revenue opportunities tied to Gibson’s enduring brand and historical significance.

    In parallel, Datavault AI will develop targeted Josh Gibson NIL strategies for its proprietary NIL exchange platform, currently being developed in exploratory collaboration with Sports Illustrated and targeted for commercial launch in the second half of 2026. These strategies will enable secure tokenization of digital twins, licensing, trading, and monetization of Gibson’s name, image, and likeness rights, creating new avenues for collectors, brands, and the broader community to engage with and support Negro Leagues history.

    Sean Gibson, Josh Gibson’s great grandson and Executive Director of the Josh Gibson Foundation, stated: “My family is incredibly proud to see my great grandfather’s legacy honored in this innovative way. With MLB now officially recognizing the Negro Leagues’ statistics and Josh’s place among baseball’s all-time greats, Datavault AI’s Josh Gibson Stablecoin and NIL strategies will bring his story to new generations through Web 3.0 technology. This is a powerful tribute during Black History Month that preserves black excellence in sports while creating real economic opportunities for the future. We look forward to working together to make his achievements accessible to fans worldwide.”

    “Josh Gibson was not only one of the greatest players in baseball history, he was a trailblazer whose excellence was denied its rightful place for decades. With MLB now officially integrating the Negro Leagues statistics, we are proud to launch the Josh Gibson Stablecoin and develop comprehensive NIL strategies on our forthcoming exchange. This initiative perfectly demonstrates how Datavault AI’s tokenization technology, AI platforms, and Information Data Exchange® can preserve cultural legacies while creating real economic opportunities. We are especially excited to celebrate Black History Month and we anticipate that we will distribute a special commemorative Josh Gibson meme coin to our shareholders in the near term. We will announce the record date for any such distribution once it has been approved by our board of directors. We anticipate that the distribution will be on the basis of one coin for every one share of Datavault AI common stock, rewarding our investors as we bridge sports history with the future of Web3.”

    To celebrate Black History Month and Josh Gibson’s monumental contributions to baseball and American history, Datavault AI anticipates that it will distribute a special commemorative Josh Gibson meme coin to its shareholders on the basis of one commemorative meme coin for every one share of Datavault AI common stock held, subject to board approval, setting of a record date and standard distribution terms, in each case which Datavault AI will announce at a later date. The commemorative meme coin will be intended as a digital collectible with potential trading availability on the IDE following distribution of the coin and launch of the IDE. This distribution continues Datavault AI’s tradition of delivering innovative, culturally significant digital assets directly to shareholders, similar to its recent Dream Bowl Meme Coin II initiative.

    As part of this collaboration, Datavault will host a private, invitation-only event at its Philadelphia headquarters to honor the legacy of Josh Gibson in observance of Black History Month. The event will convene select media, stakeholders, and community representatives and will include demonstrations of the Company’s acoustic and data technologies.

    About Datavault AI Inc.

    Datavault AI TM (Nasdaq:DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA® , ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.

    About The Josh Gibson Foundation

    The Josh Gibson Foundation believes in the endless possibilities for potential in today’s youth. By providing academic and athletic programs that foster leadership and scholarship, we create the skills necessary for tomorrow’s successes today. Our goal is to carry on the legacy of greatness and accomplishment embodied by Josh Gibson, by developing programs that help children of every ability level reach their potential. We also aim to create opportunities that set The Josh Gibson Foundation apart from other organizations and provide value for our communities. Learn more at joshgibson.org

    Forward-Looking Statements

    This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the expected operational, technical and commercial outcomes of the Company’s commercial strategy, including the potential launch of the IDE in the second half of 2026, statements regarding our declaration and/or payment of distributions to our shareholders, and our expectations regarding the terms and/or timing of the potential distribution of a special commemorative Josh Gibson meme coin to our shareholders, including whether we will proceed with such distribution, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein.

    Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks related to the ability of Datavault AI to successfully implement its commercial partnerships, collaborations and/or strategies; changes in market demand for Datavault AI’s services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

    The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

    Media Inquiries
    marketing@dvlt.ai

    Investor Contact
    ir@dvlt.ai

    Josh Gibson’s License Contact:
    Ed Schauder
    917-907-1404

    SOURCE: Datavault AI Inc

    View the original press release on ACCESS Newswire


    Continue Reading

  • Aston Martin issues another profit warning and sells F1 naming rights for £50m | Aston Martin

    Aston Martin issues another profit warning and sells F1 naming rights for £50m | Aston Martin

    Aston Martin has again warned its profits will be lower than expected and sold its permanent naming rights to its Formula One team, as the struggling British carmaker battles to stabilise its finances.

    The luxury carmaker, majority-owned by the Canadian billionaire Lawrence Stroll, said its earnings for 2025 would be worse than City forecasts, its fifth profit warning since September 2024.

    Analysts had been expecting the struggling company to post a loss of £184m at its annual results, due to be published next Wednesday.

    Aston Martin delivered nearly 10% fewer cars last year than in 2024 – 5,448 in total – as US trade tariffs battered sales and the company fell short on lucrative special edition deliveries. Shares fell as much as 4% on Friday morning before recovering some ground, down 2%.

    Since taking control in 2020, Stroll has tried to turn around the manufacturer, which is best known for featuring in the James Bond franchise, by introducing new models and repeatedly raising cash.

    But the succession of profit warnings has battered the company’s shares, which have lost about half their value over the past year.

    Cash reserves are about £250m, roughly stable compared with six months ago but down from £360m at the start of 2025. The carmaker’s debt pile has also soared 70% since the start of 2024.

    In a fresh attempt to shore up its balance sheet, Aston Martin will permanently sell the right to use its name in Formula One to its own F1 team for £50m, it said on Friday. The team is operated by AMR GP Holdings, a separate company also controlled by Stroll – meaning the deal is effectively an extra injection of funds from the owner.

    Because the billionaire, who owns 32% of the carmaker, sits on both sides of the deal, it requires approval from shareholders. However, that appears to be a formality; investors representing just over half of the company, including Stroll’s investment vehicle, plus Geely and Mercedes-Benz, have already committed to vote in favour.

    Aston Martin did a similar deal in 2024 that gave the F1 team naming rights until 2055.

    Despite the gloom, the company said on Friday that about 500 of its new Valhalla models would be delivered in 2026 in a boost for its prospect. Priced at £850,000 each, only 999 will ever be made. More than half have already been sold.

    It is the latest twist in a painful five-year turnaround marked by perennial heavy losses, a dealer inventory crisis and persistent production challenges. Donald Trump’s US tariff war, launched last year, compounded its difficulties.

    Trump imposed a 25% tariff on car imports last April, adding significant costs to Aston Martin’s cars in one of its key markets. A subsequent UK-US tariff agreement, struck in May 2025, capped duties on 100,000 British-made cars at 10% from the end of June, offering some relief.

    In October, Aston Martin slashed £300m from its investment plans and cut spending on developing new cars, citing the impact of tariffs and extremely subdued Chinese demand.

    It also called for “more proactive support” from British ministers at the time, in the face of tariffs, urging them to “protect the interests of small-volume manufacturers, like Aston Martin, who provide thousands of jobs”.

    Continue Reading

  • Five ways increased militarization could change scientific careers

    Five ways increased militarization could change scientific careers

    Ukrainian soldiers test drones in Donetsk, Febuary 2025.Credit: Serhii Mykhalchuk/Global Images Ukraine via Getty

    Military budgets are growing, especially in larger economies. In 2024, global military spending totalled U$2.7 trillion1, a 9.4% increase in real terms over the previous year, according to the Stockholm International Peace Research Institute (SIPRI), a think tank specializing in conflict, peace and weapons. Just two countries, China and the United States, accounted for almost half of the total.

    At their two-day summit in June 2025, all but one of the 32 North Atlantic Treaty Organization (NATO) member countries agreed to spend 5% of gross domestic product (GDP) on defence and security by 2035, in response to “profound security threats and challenges” — chiefly perceived threats from Russia and from terrorism. If achieved, this would be an enormous escalation in spending. UK military expenditure of 5% of GDP would amount to half of what the country spends on its National Health Service2 (NHS).

    But nations have considerable leeway to decide what falls under this umbrella, which can include research and development (R&D) funding. Spain, for example, which opted out of the 5% target, has called for a broader view of defence spending, to encompass areas such as quantum computing.

    What impact, if any, will defence-spending pledges have on research budgets? Some scholars who work on science funding, defence and peace, such as Lucy Suchman, a technology-focused sociologist at Lancaster University, UK, say that certain scientific fields could benefit (such as artificial intelligence) but others lose out (such as climate science) as funding priorities shift increasingly towards militarization.

    One study of 183 countries between 1989 and 2022 found that higher defence spending was associated with fewer trademark applications and fewer people working on R&D3. In many countries, increased government spending on defence exists alongside lowered spending on other research. In the Organisation for Economic Co-operation and Development (OECD) countries, public R&D spending on health declined by 11.5% from 2020 to 2024, while spending on defence R&D rose by 17%4. Government spending in the OECD on ‘general advancement of knowledge’ has also started to decline.

    Nature’s careers team spoke to more than ten researchers working on science, peace and defence. They highlighted five interrelated themes that demonstrate changes to science — and to the careers researchers might expect to have — that could ensue in a more militarized world.

    More nationalism, less collaboration

    Evidence suggests that admitting more international graduate students leads to economic benefits, yet Canada, the United States, the United Kingdom and Australia are among those countries making it harder for international students to secure visas. China and the United States generate more influential research when they collaborate than when they do not, yet this collaboration is declining5. Overall, immigration controls, data-access restrictions and a focus on security are creating a more restricted environment for science.

    On the basis of current trends, science is likely to become more constrained by ideas of national self-interest and scientific self-sufficiency, against a backdrop of increased military spending. “There’s been a rise of nationalism, and scientific cooperation has been influenced by that,” says Caroline Wagner, a public-policy researcher at Ohio State University in Columbus.

    Nevia Vera, an international-relations researcher at the National University of the Center of Buenos Aires Province in Tandil, Argentina, dates this trend to 2018, when the United States launched its China Initiative to counter potential espionage in US laboratories and businesses. That year, China surpassed the United States as the largest source of peer-reviewed articles5, and publications authored jointly by Chinese and US authors started to decline from a peak of 16% of the total number from both countries. Sino–US co-authored papers in the main Web of Science databases dropped by more than 10% between 2018 and 2024, according to Li Tang, a science-policy researcher at Fudan University in Shanghai, China.

    But the collaborations haven’t ended entirely, which echoes previous ups and downs in international research. In 1984, Bill Foster started working as a physicist at the Fermi National Accelerator Laboratory near Chicago, Illinois. Even during the cold war, Foster says, there were Russian physicists working well alongside US ones — even though “you always knew that there was a KGB person”, he adds. “You could tell: he was the guy … who didn’t really know the physics.”

    Scandinavian leaders are seen around a table for a NATO meeting with Volodymyr Zelenskyy.

    A NATO summit with Ukrainian leader Volodymyr Zelenskyy in the Hague, Netherlands, June 2025.Credit: Emmi Korhonen/Sipa US/Alamy Live News

    Foster was elected to the US House of Representatives as a Democrat in 2013 and has co-sponsored a bipartisan bill in Congress that would allow some Russians working in science, technology, engineering and mathematics (STEM) to gain permanent residence in the United States. He argues that this “will simultaneously kick the legs out from under Russian President Vladimir Putin’s war effort — to lose some of the best and brightest” Russians — and “do something that will be of permanent value to the United States”.

    Sylvia Schwaag Serger, an economic historian at Lund University in Sweden, thinks that it would take years, if not decades, to reverse the overall decline in international research collaborations. But she also speculates that international research career moves could lose some of their lustre in the longer term. “Whereas before, international experience often was generally considered positive,” she notices that in some countries, “researchers are reconsidering whether it’s actually helping their career”, she says.

    Regional realignment

    Although overall collaboration between scientists of different nations might decrease, some expect this to be more of a splintering effect, with researchers collaborating increasingly within regional blocs or geopolitical alliances. There is already growing collaboration in Europe, in Asia and among OECD countries, according to Schwaag Serger.

    For instance, while their country’s relationship with the United States has cooled in the past few years, Chinese researchers have increased their collaborations with colleagues in Africa, Asia and Latin America.

    But overall, Tang emphasizes, “the decreasing collaboration between scientists in China and the US is not being compensated for by increased collaboration between China and other countries, such as India and Russia”.

    Most countries have limited scope to manoeuvre around the big military spenders (the biggest spenders among which are the United States, China, Russia, Germany and India1). Vera calls these countries’ influence “the trends of great powers”. Although the geopolitical situation is more complex now than during the cold war, scientists in many nations could again feel pressed to align with one set of countries or another.

    More scientific inequality

    Also widening is the technology gap between countries. A report by United Nations secretary-general António Guterres details how the R&D benefits of military spending tend to pool in a few countries6, disadvantaging low-income nations where the military spends little on R&D. “Technology advances so quickly that countries cannot catch up” to scientific superpowers such as the United States, the European Union and China, Vera thinks. Some AI researchers have warned that this type of technological–military competition could spill over into conflict7.

    Although the United States and China will remain interested in parts of Latin America and Africa for minerals crucial to technological transition and rearmament, Vera worries about these relationships being extractive rather than genuine partnerships. The United States has embraced a transactional approach to security assistance, for instance, by supporting peace and security efforts in the Democratic Republic of the Congo in exchange for influence over mineral resources.

    Continue Reading

  • Samsung Solve for Tomorrow Team Paraspeak Wins Top Honour at AI Summit 2026 – Samsung Newsroom India

    Samsung Solve for Tomorrow Team Paraspeak Wins Top Honour at AI Summit 2026 – Samsung Newsroom India

    Team Paraspeak was among four winners of Samsung Solve for Tomorrow 2025

    The team’s Solve for Tomorrow winning idea gets YUVAi Global Youth Award at the summit

    YUVAi Global Youth Award is a Ministry of Electronics and Information Technology, Government of India initiative

    Pranet Khetan, one of the winners of Samsung India’s flagship innovation programme, Samsung Solve for Tomorrow 2025, has secured first prize at the ongoing India AI Impact Summit 2026.

     

    The 16-year-old was among the four national winners of Samsung Solve for Tomorrow 2025, a pan-India innovation competition that empowers the youth to create tech-based solutions to solve real-world problems.

     

    During Samsung Solve for Tomorrow 2025, Pranet showcased Paraspeak, a real-time, speaker-independent speech enhancement device that converts slurred speech (dysarthria) into clear communication using deep-learning algorithms, helping individuals communicate confidently.

     

    Paraspeak got mentorship from Samsung experts and incubation at FITT, IIT Delhi’s incubation lab in 2025 during the programme.

     

    At the ongoing AI Impact summit, Paraspeak won the YUVAi Global Youth Challenge, Ministry of Electronics and Information Technology, Government of India initiative, securing a prize of ₹15 lakh. The competition attracted more than 2,500 entries from 38 countries, highlighting strong global participation from young innovators developing solutions aligned with social and developmental priorities.

     

    This achievement reflects the growing impact of emerging talent supported through Samsung’s innovation ecosystem. Samsung Solve for Tomorrow equips participants with mentorship, structured learning, and industry exposure, enabling them to transform ideas into practical, scalable solutions with real-world relevance.

     

    During Samsung Solve for Tomorrow 2025, the top four winning teams — Percevia (Bengaluru), NextPlay.AI (Aurangabad), Prithvi Rakshak (Palamu) and Paraspeak (Gurugram)— received INR 1 crore in incubation grants and will continue to develop their prototypes into scalable real-world solutions with mentorship support at IIT Delhi’s FITT Labs.

     

    The India AI Impact Summit held at New Delhi convened global policymakers, industry leaders, researchers, and innovators to showcase transformative AI solutions tackling global challenges.

    Continue Reading

  • Increasing the number of coronary interventions in patients with acute myocardial infarction does not appear to reduce death rates

    Increasing the number of coronary interventions in patients with acute myocardial infarction does not appear to reduce death rates

    Key takeaways  

    • Primary percutaneous coronary intervention (PCI) is a life-saving procedure that is used to restore blood flow following an acute myocardial infarction. 
    • An analysis of data from 21 European countries did not reveal a significant association between increased numbers of primary PCI procedures and reduced mortality rates. 
    • Subsequent analyses will assess additional factors including the timing of the procedure relative to symptom onset, operator experience and variations in practice between different centres and countries. 
    • Data such as these inform efforts to improve the treatment of cardiovascular disease across Europe and highlight the need for more effective prevention strategies. 

     

    Munich, Germany – 20 February 2026: An increase in the number of percutaneous coronary interventions does not appear to have resulted in reduced mortality rates, according to results presented today at the EAPCI Summit 2026.[1] The summit is a new event organised by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), an association of the European Society of Cardiology (ESC). 

    Primary percutaneous coronary intervention (PCI) is a life-saving procedure used to restore blood flow as soon as possible after the onset of a heart attack (myocardial infarction [MI]). It involves unblocking the coronary arteries, often using a stent inserted via a catheter from the groin or wrist. 

    Study presenter, Ali Malik from King’s College London, UK, noted that statistical analyses are ongoing to evaluate the impact of primary PCI procedures across Europe. “It is well established that primary PCI plays a pivotal role in reducing mortality after MI; however, significant variability exists at local, national and regional levels in the provision of primary PCI and associated patient outcomes,” he stated. 

    The investigators analysed data from the ESC Atlas of Cardiology and the ESC Atlas in Interventional Cardiology,[2] which compile statistics on cardiovascular disease (CVD) burden, risk factors, outcomes and management practices to highlight current trends, gaps and disparities in the quality of care. ESC Atlas data were integrated with datasets from the World Health Organization, the Institute for Health Metrics and Evaluation and from Eurostat, covering 21 European countries. The association between primary PCI procedures per million inhabitants and age-standardised acute MI mortality rates was assessed, adjusting for confounding variables including the prevalence of CVD and gross domestic product (GDP) per capita.  

    Across the countries analysed, higher GDP per capita was associated with lower age-standardised MI mortality rates, demonstrating a moderate inverse correlation (population correlation coefficient=−0.54; p=0.004). Conversely, greater CVD prevalence was associated with higher age-standardised MI mortality rates (population correlation coefficient=+0.45; p=0.02). 

    Following adjustment for GDP per capita and CVD prevalence, a moderate positive correlation emerged: higher rates of primary PCI were associated with increased age-standardised MI mortality (population correlation coefficient=+0.68; p<0.001). 

    A weak inverse association was identified indicating that a greater number of primary PCI procedures performed per interventional cardiologist was associated with lower MI mortality rates (population correlation coefficient=−0.27; p=0.23). 

    Co-investigator, Sukruth Pradeep Kundur, also from King’s College London, commented: “One would anticipate that increased provision of primary PCI would yield lower mortality rates; therefore, we will conduct additional analyses to elucidate why this trend is not evident in our preliminary findings. The observed association with procedural workload highlights the significance of operator expertise. In addition, system-level factors include inter-centre variability and the interval between symptom onset and access to primary PCI.” 

    Senior author, Doctor Sanjay Sivalokanathan from the Mount Sinai Health System in New York, USA, concluded: “The global rise in cardiometabolic risk factors appears to play a meaningful role in the clinical complexity of patients presenting with acute coronary syndromes. As such, PCI may be challenging in certain settings, highlighting the importance of operator experience and advanced interventional strategies. These developments emphasise the need for collaborative, multidisciplinary approaches, while prevention remains the cornerstone of reducing the overall burden of cardiovascular disease and associated mortality.” 

    ENDS  

     

    Continue Reading

  • Deloitte comments on ONS retail sales figures

    Deloitte comments on ONS retail sales figures

    About Deloitte

    Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

    Deloitte provides industry-leading audit and assurance, tax and legal, consulting, financial advisory, and risk advisory services to nearly 90% of the Fortune Global 500® and thousands of private companies. Our people deliver measurable and lasting results that help reinforce public trust in capital markets, enable clients to transform and thrive, and lead the way toward a stronger economy, a more equitable society, and a sustainable world. Building on its 175-plus year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte’s approximately 457,000 people worldwide make an impact that matters at www.deloitte.com.


    Continue Reading

  • U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    • First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL
    • Approval supported by data from the Phase 3 AMPLIFY trial
    • Regimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease management

    NORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1

    This milestone updates the treatment of CLL in the first-line setting, establishing the VENCLEXTA and acalabrutinib combination as the first and only all-oral, fixed-duration regimen for previously untreated patients. The regimen supports current standards of care by offering patients the potential for time off treatment and giving providers a new, targeted option that combines two classes of oral medications for CLL.

    “This FDA approval marks a significant milestone for AbbVie and, more importantly, for people living with CLL,” said Svetlana Kobina, vice president, global medical affairs, oncology, AbbVie. “As the first and only all-oral, fixed-duration combination regimen for previously untreated patients, the VENCLEXTA plus acalabrutinib approval expands choice and flexibility for patients and providers navigating complex treatment decisions in CLL.”

    CLL is one of the most common forms of leukemia in adults and is a type of cancer that can develop from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).2 While outcomes have improved in recent years, patients often face long treatment durations and ongoing disease management challenges.

    “With the FDA approval of the combination of venetoclax and acalabrutinib for use as a front-line therapy in CLL, patients in the USA now have an all oral, time-limited option that can be important for many in choosing their treatment,” said Dr. Brian Koffman, co-founder and chief medical officer emeritus, CLL Society. “CLL Society is pleased to see the number of choices available for patients growing.”

    About the AMPLIFY Study
    AMPLIFY is an AstraZeneca-sponsored, global, multi-center Phase 3 trial evaluating VENCLEXTA plus acalabrutinib alone or combined with obinutuzumab versus chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab [FCR] or bendamustine-rituximab [BR]) in patients with previously untreated CLL without del(17p) or TP53 mutation.1 VENCLEXTA plus acalabrutinib were administered for a fixed duration of 14 cycles, each consisting of 28 days, while chemoimmunotherapy was administered for six cycles according to regimens. VENCLEXTA was started on cycle 3 of 14 with a 5-week ramp-up schedule.

    Results from the AMPLIFY study showed that the fixed-duration combination regimen of VENCLEXTA and acalabrutinib was superior to FCR/BR chemoimmunotherapy. Study results showed the combination regimen of VENCLEXTA and acalabrutinib reduced the risk of disease progression or death by 35% versus chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038). Median progression-free survival (PFS) was not reached versus 47.6 months for chemoimmunotherapy. The safety profile of the VENCLEXTA and acalabrutinib combination regimen is consistent with the known safety profile of each individual therapy alone. In CLL/SLL, the most common adverse reactions (≥20%) for VENCLEXTA when given in combination with acalabrutinib are neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19. The most common serious adverse reactions (≥2%) in patients receiving V+A were COVID-19, including COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%). In patients treated with VENCLEXTA plus acalabrutinib, the incidence of tumor lysis syndrome was 0.3%. No new safety signals were observed in the AMPLIFY study.3

    About VENCLEXTA® (venetoclax) 
    VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLEXTA targets the BCL-2 protein and works to help restore the process of apoptosis.

    VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.

    VENCLEXTA® (venetoclax) U.S. Uses and Important Safety Information4
    Uses
    VENCLEXTA is a prescription medicine used:

    • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    • in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with
      newly diagnosed acute myeloid leukemia (AML) who:

    – are 75 years of age or older, or
    – have other medical conditions that prevent the use of standard chemotherapy.

    It is not known if VENCLEXTA is safe and effective in children.

    Important Safety Information
    What is the most important information I should know about VENCLEXTA?
    VENCLEXTA can cause serious side effects, including:

    Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS.

    You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you get any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

    Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

    Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you get symptoms of TLS. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may check again for your risk of TLS and change your dose.

    Who should not take VENCLEXTA?
    Patients taking certain medicines during the beginning of VENCLEXTA (when the dose is being slowly increased) are at increased risk of TLS.

    • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
    • Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

    Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

    • have kidney or liver problems.
    • have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
    • have a history of high uric acid levels in your blood or gout.
    • are scheduled to receive a vaccine. You should not receive a “live vaccine” before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
    • are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby.

    Females who are able to become pregnant:
    – Your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA.
    – Use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA.
    – If you become pregnant or think you are pregnant, tell your healthcare provider right away.

    • are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk.
      Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.

    What should I avoid while taking VENCLEXTA?
    You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit during treatment with VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

    What are the possible side effects of VENCLEXTA?
    VENCLEXTA can cause serious side effects, including:

    • Low white blood cell counts (neutropenia). Your healthcare provider will do blood tests to check your blood count during treatment with VENCLEXTA and may pause dosing of VENCLEXTA or give you medicines to help treat your neutropenia if it is severe.
    • Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you get a fever or any signs of infection during treatment with VENCLEXTA.

    Tell your healthcare provider right away if you get a fever or any signs of an infection during treatment with VENCLEXTA.

    The most common side effects of VENCLEXTA when used in combination with acalabrutinib in people with CLL or SLL include low white blood cell count, headache, diarrhea, muscle and bone pain, and COVID-19.

    The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell count; low platelet count; low red blood cell count; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

    The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.

    Your healthcare provider may temporarily stop VENCLEXTA treatment, decrease your dose, or completely stop treatment if you get severe side effects.

    VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

    These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

    You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.

    The full U.S. prescribing information, including Medication Guide, for VENCLEXTA can be found here. Globally, prescribing information varies; refer to the individual country product label for complete information.

    About AbbVie in Oncology
    AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

    Today, our expansive oncology portfolio is comprised of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 35 investigational medicines across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit us at http://www.abbvie.com/oncology.

    About AbbVie
    AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. 

    AbbVie Forward-Looking Statements
    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    References:

    1. Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at: https://clinicaltrials.gov/study/NCT03836261. Accessed June 30, 2025.
    2. American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed January 26, 2026.
    3. Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, Phase 3 AMPLIFY trial. Blood. 2024;144(Suppl 1):1009. Available at: https://ashpublications.org/blood/article/144/Supplement%201/1009/530876/Fixed-Duration-Acalabrutinib-Plus-Venetoclax-with. Accessed January 26, 2026.
    4. Summary of Product Characteristics for VENCLEXTA (venetoclax).

     

     

    SOURCE AbbVie


    Continue Reading

  • Apollo Provides $1 Billion Hybrid Capital Solution to AldarApollo Global Management

    Apollo Provides $1 Billion Hybrid Capital Solution to AldarApollo Global Management

    Transaction marks Apollo’s fifth investment in Aldar and the region’s largest corporate hybrid private placement 

    Builds on Apollo’s long-term strategic partnership with Aldar, with total transactions totalling approximately $2.9 billion to date

    Investment to support Aldar’s transformational growth plans and capital structure optimization

    NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds have invested $1 billion in subordinated hybrid notes issued by Aldar Properties PJSC (“Aldar”), a leading UAE based real estate developer and investment manager. The investment builds on Apollo’s long-term strategic partnership with Aldar and represents Apollo’s fifth investment in Aldar since 2022, bringing aggregate commitments to $2.9 billion to date.

    Proceeds from the investment are intended to support Aldar’s balance sheet flexibility and strength, as well as its growth agenda, which includes landbank replenishment, expansion of its develop-to-hold portfolio, and strategic acquisitions.

    Apollo Partner Jamshid Ehsani said, “Completing our fifth investment with Aldar speaks directly to Apollo’s ability to structure flexible capital solutions that are responsive to the needs of both our corporate clients and our investors. Since our first transaction in 2022, Aldar has gone from strength to strength, with robust performance and portfolio expansion overseen by an experienced management team. This latest investment reflects Apollo’s continued commitment to Abu Dhabi and the broader region.”

    Faisal Falaknaz, Group Chief Financial and Sustainability Officer at Aldar, said: “This transaction highlights the strength of our long-standing partnership with Apollo and the continued confidence of major institutional investors in Aldar’s strategy, financial management and growth trajectory. The issuance provides Aldar with long-term, flexible capital that enhances balance sheet resilience and supports our ability to capitalise on attractive opportunities across our core markets. Importantly, it elevates Aldar’s share of stable, recurring income generated by AIP’s high quality, diversified portfolio, which will continue to expand through acquisitions and our substantial develop-to-hold pipeline that is now valued at close to $5 billion.”

    The transaction is among the largest-ever foreign direct investments in Abu Dhabi’s private sector and the largest corporate hybrid private placements in the region.

    It also marks the latest transaction for Apollo’s High Grade Capital Solutions business, which serves as a capital partner to many leading global companies. Apollo believes its ability to provide customized, long-dated investments is reinforced by the number of its repeat clients, having provided multiple large-scale solutions for Aldar, BP, Sony, Vonovia, Air France and the Adani-backed Mumbai Airport.

    About Apollo

    Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com.

    Apollo Contacts

    Noah Gunn
    Global Head of Investor Relations
    Apollo Global Management, Inc.
    (212) 822-0540
    IR@apollo.com

    Joanna Rose
    Global Head of Corporate Communications
    Apollo Global Management, Inc.
    (212) 822-0491
    Communications@apollo.com

    About Aldar

    Aldar is the leading real estate developer, manager, and investor in Abu Dhabi, with a growing presence across the United Arab Emirates, the Middle East North Africa, and Europe.

    The company has two core business segments, Aldar Development and Aldar Investment.

    Aldar Development is a master developer of a 60 million sqm strategic landbank, creating integrated and thriving communities across Abu Dhabi, Dubai, and Ras Al Khaimah’s most desirable destinations. The delivery of Aldar’s developments is managed by Aldar Projects, which is also a key partner of the Abu Dhabi government in delivering housing and infrastructure projects across the UAE’s capital. Internationally, Aldar Development wholly owns UK real estate developer London Square, as well as a majority stake in leading Egyptian real estate development company, SODIC.

    Aldar Investment houses a core asset management business comprising a portfolio of more than AED 49 billion worth of investment grade and income-generating real estate assets diversified across retail, residential, commercial, logistics, and hospitality segments. It manages four core platforms: Aldar Investment Properties, Aldar Hospitality, Aldar Education, and Aldar Estates.

    For more information on Aldar please visit www.aldar.com or follow us on:

    https://www.instagram.com/aldar/?hl=en

    https://www.linkedin.com/company/110553/admin/feed/posts/

    https://x.com/aldartweets?lang=en

    Aldar Contacts

    Obaid Al Yammahi
    Aldar Properties
    +971 2 810 5555
    Sarah Abdelbary
    Brunswick
    +971 2 234 4600
    aldar@brunswickgroup.com


    Continue Reading

  • Chip-processing method could assist cryptography schemes to keep data secure | MIT News

    Chip-processing method could assist cryptography schemes to keep data secure | MIT News

    Just like each person has unique fingerprints, every CMOS chip has a distinctive “fingerprint” caused by tiny, random manufacturing variations. Engineers can leverage this unforgeable ID for authentication, to safeguard a device from attackers trying to steal private data.

    But these cryptographic schemes typically require secret information about a chip’s fingerprint to be stored on a third-party server. This creates security vulnerabilities and requires additional memory and computation.

    To overcome this limitation, MIT engineers developed a manufacturing method that enables secure, fingerprint-based authentication, without the need to store secret information outside the chip.

    They split a specially designed chip during fabrication in such a way that each half has an identical, shared fingerprint that is unique to these two chips. Each chip can be used to directly authenticate the other. This low-cost fingerprint fabrication method is compatible with standard CMOS foundry processes and requires no special materials.

    The technique could be useful in power-constrained electronic systems with non-interchangeable device pairs, like an ingestible sensor pill and its paired wearable patch that monitor gastrointestinal health conditions. Using a shared fingerprint, the pill and patch can authenticate each other without a device in between to mediate.

    “The biggest advantage of this security method is that we don’t need to store any information. All the secrets will always remain safe inside the silicon. This can give a higher level of security. As long as you have this digital key, you can always unlock the door,” says Eunseok Lee, an electrical engineering and computer science (EECS) graduate student and lead author of a paper on this security method.

    Lee is joined on the paper by EECS graduate students Jaehong Jung and Maitreyi Ashok; as well as co-senior authors Anantha Chandrakasan, MIT provost and the Vannevar Bush Professor of Electrical Engineering and Computer Science, and Ruonan Han, a professor of EECS and a member of the MIT Research Laboratory of Electronics. The research was recently presented at the IEEE International Solid-States Circuits Conference.

    “Creation of shared encryption keys in trusted semiconductor foundries could help break the tradeoffs between being more secure and more convenient to use for protection of data transmission,” Han says. “This work, which is digital-based, is still a preliminary trial in this direction; we are exploring how more complex, analog-based secrecy can be duplicated — and only duplicated once.”

    Leveraging variations

    Even though they are intended to be identical, each CMOS chip is slightly different due to unavoidable microscopic variations during fabrication. These randomizations give each chip a unique identifier, known as a physical unclonable function (PUF), that is nearly impossible to replicate.

    A chip’s PUF can be used to provide security just like the human fingerprint identification system on a laptop or door panel.

    For authentication, a server sends a request to the device, which responds with a secret key based on its unique physical structure. If the key matches an expected value, the server authenticates the device.

    But the PUF authentication data must be registered and stored in a server for access later, creating a potential security vulnerability.

    “If we don’t need to store information on these unique randomizations, then the PUF becomes even more secure,” Lee says.

    The researchers wanted to accomplish this by developing a matched PUF pair on two chips. One could authenticate the other directly, without the need to store PUF data on third-party servers.

    As an analogy, consider a sheet of paper torn in half. The torn edges are random and unique, but the pieces have a shared randomness because they fit back together perfectly along the torn edge.

    While CMOS chips aren’t torn in half like paper, many are fabricated at once on a silicon wafer which is diced to separate the individual chips.

    By incorporating shared randomness at the edge of two chips before they are diced to separate them, the researchers could create a twin PUF that is unique to these two chips.

    “We needed to find a way to do this before the chip leaves the foundry, for added security. Once the fabricated chip enters the supply chain, we won’t know what might happen to it,” Lee explains.

    Sharing randomness

    To create the twin PUF, the researchers change the properties of a set of transistors fabricated along the edge of two chips, using a process called gate oxide breakdown.

    Essentially, they pump high voltage into a pair of transistors by shining light with a low-cost LED until the first transistor breaks down. Because of tiny manufacturing variations, each transistor has a slightly different breakdown time. The researchers can use this unique breakdown state as the basis for a PUF.

    To enable a twin PUF, the MIT researchers fabricate two pairs of transistors along the edge of two chips before they are diced to separate them. By connecting the transistors with metal layers, they create paired structures that have correlated breakdown states. In this way, they enable a unique PUF to be shared by each pair of transistors.

    After shining LED light to create the PUF, they dice the chips between the transistors so there is one pair on each device, giving each separate chip a shared PUF.

    “In our case, transistor breakdown has not been modeled well in many of the simulations we had, so there was a lot of uncertainty about how the process would work. Figuring out all the steps, and the order they needed to happen, to generate this shared randomness is the novelty of this work,” Lee says.

    After finetuning their PUF generation process, the researchers developed a prototype pair of twin PUF chips in which the randomization was matched with more than 98 percent reliability. This would ensure the generated PUF key matches consistently, enabling secure authentication.

    Because they generated this twin PUF using circuit techniques and low-cost LEDs, the process would be easier to implement at scale than other methods that are more complicated or not compatible with standard CMOS fabrication.

    “In the current design, shared randomness generated by transistor breakdown is immediately converted into digital data. Future versions could preserve this shared randomness directly within the transistors, strengthening security at the most fundamental physical level of the chip,” Lee says.

    “There is a rapidly increasing demand for physical-layer security for edge devices, such as between medical sensors and devices on a body, which often operate under strict energy constraints. A twin-paired PUF approach enables secure communication between nodes without the burden of heavy protocol overhead, thereby delivering both energy efficiency and strong security. This initial demonstration paves the way for innovative advancements in secure hardware design,” Chandrakasan adds.

    This work is funded by Lockheed Martin, the MIT School of Engineering MathWorks Fellowship, and the Korea Foundation for Advanced Studies Fellowship.

    Continue Reading

  • Asia Funds & Financial Services Newsletter | Insights

    Sidley’s Asia Funds and Financial Services Newsletter discusses important regulatory and enforcement developments that affect financial institutions, investment advisers, and investment funds operating in the Asia-Pacific region in a fast-changing regulatory landscape. In this issue, we cover (among other things) the impact of the U.S. Outbound Investment Rules on managers with Chinese investment exposure, a critical review of the Hong Kong Securities and Futures Commission (SFC) enforcement process, as well as Singapore’s proposals to tighten liquidity management guidelines for fund managers.

    Featured articles

    U.S. Outbound Investment Rules Reshape Fund Management Strategy

    New U.S. regulations on outbound investments are fundamentally transforming fund management, particularly affecting managers with Chinese investment exposure. Three key developments are driving this change: (i) the Outbound Investment Regulations (OIR) that took effect January 2, 2025; (ii) the Comprehensive Outbound Investment National Security (COINS) Act enacted December 18, 2025; and (iii) new Treasury FAQs issued December 23, 2025.

    Expanding Scope Under COINS Act

    The existing OIR, as detailed in our May 2025 Update, established prohibitions and notification requirements for U.S. person investments into China-related entities in semiconductors, artificial intelligence, and quantum computing. The COINS Act significantly expands this framework in three ways.

    First, “countries of concern” will expand beyond China, Hong Kong, and Macau to include Russia, Iran, North Korea, Cuba, and Venezuela under the Maduro regime. Second, covered foreign persons will include Chinese Communist Party Central Committee members and political leadership of countries of concern, plus entities “subject to their direction or control.” Third, covered technologies expand to five sectors, adding hypersonic systems to the existing categories, with Treasury authorized to designate additional technologies.

    Key Clarifications on Public Securities

    The new Treasury FAQs provide crucial guidance on the publicly traded securities exception. Settlement timing, not execution date, determines exception eligibility. If settlement occurs after listing, acquisitions fall within the exception, even for pre–initial public offering (IPO) subscriptions. Treasury reversed its position on minority shareholder protections, now considering director nomination rights as standard protections when generally available to similarly situated shareholders, though director appointment rights remain restricted.

    Enhanced Due Diligence Requirements

    Each investment requires individual assessment through “reasonable and diligent inquiry” involving public information searches, target questioning when possible, and contractual representations. The COINS Act authorizes Treasury to publish a nonexhaustive list of covered entities, but transaction-specific diligence will remain necessary.

    Impact on Limited Partner Investments

    The COINS Act may fundamentally alter limited partner (LP) investment frameworks. Currently, U.S. LPs can invest in non-U.S. funds with contractual assurances that capital won’t fund prohibited transactions. Under COINS, LPs would need assurances against any investment in entities from countries of concern, regardless of sector involvement, potentially severely restricting U.S. participation in non-U.S. funds with such exposure.

    Administrative Enhancements

    The COINS Act provides Treasury with new tools including nonbinding feedback mechanisms for transaction guidance, voluntary self-disclosure frameworks for violations, and expanded exception categories covering de minimis transactions, ancillary transactions, ordinary business activities, and regulated foreign investment companies.

    Operational Implications

    Fund managers face comprehensive operational changes. Investment strategies require reassessment, with potential pivots toward allied nations and sophisticated screening mechanisms. Due diligence processes become more complex and time-consuming, examining ownership structures, revenue sources, and potential connections to restricted entities. Compliance frameworks need substantial updating with new monitoring systems and revised fund documentation. Different fund types face unique challenges. Private equity managers must navigate complex exit strategies with potentially limited strategic buyers, while venture capital funds may redirect focus from restricted country startups toward opportunities in allied nations.

    Implementation Timeline

    Current OIR rules remain effective while Treasury has 450 days from December 18, 2025, to implement COINS Act regulations. Fund managers must immediately audit existing portfolio exposure, update compliance programs, and enhance investor communications while preparing for substantially more restrictive requirements. The changes represent more than additional regulation — they fundamentally reshape global fund management toward domestic and allied nation investments with enhanced compliance requirements and permanent structural market changes.

    SFC Enforcement Activity Under Scrutiny: Review Identifies Critical Gaps in Case Management and Cross-Border Corporation

    The Process Review Panel (PRP) annual report (released December 2025) presents a comprehensive evaluation of SFC enforcement capabilities, revealing both operational strengths and persistent systemic challenges that affect regulatory effectiveness. Of the 60 cases reviewed, 24 were enforcement matters, providing significant insight into the SFC’s regulatory performance during a period of evolving market complexity.

    Case Management and Procedural Efficiency

    The report identifies worrisome delays in case processing, with enforcement cases ranging from three months’ to 16 years’ completion time. Four specific cases highlighted critical bottlenecks in SFC’s internal machinery. One case demonstrated a particularly problematic nine-month delay in referring matters to the Department of Justice, followed by an additional eight-month period to secure approval for Market Misconduct Tribunal proceedings. This 17-month administrative lag underscores fundamental inefficiencies in interdivisional coordination and external referral mechanisms.

    Another case revealed excessive delays between investigation completion and disciplinary action, with over one year elapsing before issuing a Notice of Proposed Disciplinary Action despite the case’s straightforward nature. The PRP’s criticism here reflects broader concerns about the SFC’s ability to balance thoroughness with timeliness in regulatory responses.

    Cross-Boundary Enforcement Challenges

    The report emphasizes growing complexities in cross-border investigations, particularly involving Mainland suspects. While acknowledging the SFC’s strengthened cooperation framework with the China Securities Regulatory Commission through various memoranda of understanding (MOUs), including the significant 2023 bilateral agreement, practical enforcement outcomes remain limited. Several cases concluded with no further action despite substantial investigative investment, primarily due to suspects’ being based in or having absconded to the Mainland.

    The PRP’s observations suggest that while cooperation mechanisms exist, their practical application requires further refinement. The panel encourages deeper collaboration with Mainland authorities, recognizing that successful cross-boundary enforcement is increasingly critical to Hong Kong’s regulatory effectiveness given integrated market structures.

    Strategic Planning and Resource Optimization

    Perhaps most concerning are cases where significant SFC resources were expended without meaningful enforcement outcomes. The report describes investigations involving fictitious transactions and false disclosures that ultimately yielded no disciplinary or legal action due to suspects being unlocatable or having limited realizable assets. This pattern suggests potential inadequacies in early case assessment and strategic planning.

    The PRP recommends more proactive measures to protect investor interests, including earlier asset freezing orders and improved coordination with related regulatory bodies such as the Accounting and Financial Reporting Council. These suggestions reflect growing expectations that regulators should act preventively rather than merely reactively.

    Technological Advancement and Operational Modernization

    The report highlights technology as both a solution and an ongoing challenge. While acknowledging the SFC’s adoption of advanced technologies and the positive impact of the March 2023 investor identification regime, historical cases demonstrate significant inefficiencies in handling voluminous trading data. The PRP encourages continued exploration of artificial intelligence and other technologies to enhance investigative efficiency, recognizing that technological sophistication is essential for modern financial regulation.

    Overall Assessment and Future Priorities

    The SFC’s responses to PRP recommendations demonstrate it has implemented various measures to improve efficiency, including streamlined referral processes, expanded expert pools, and coordination mechanisms with law enforcement partners. However, the fundamental challenges revealed — lengthy processing times, cross-boundary enforcement difficulties, and resource allocation inefficiencies — suggest deeper structural issues requiring sustained attention. 

    The report coincides with increasingly complex regulatory challenges, including cryptocurrency activities, algorithmic trading, and sophisticated cross-border market manipulation schemes. While the SFC plainly demonstrates its commitment to improvement and has established robust frameworks for international cooperation, translating these frameworks into successful enforcement outcomes remains challenging. The PRP’s recommendations provide a roadmap for addressing these systemic issues, emphasizing the need for more proactive case management, enhanced technological adoption, and deeper cross-boundary collaboration to maintain Hong Kong’s position as a leading international financial center.

    MAS Proposes Updates to Liquidity Risk Management Guidelines for Fund Managers

    In December 2025, the Monetary Authority of Singapore (MAS) issued a consultation paper proposing amendments to the current Guidelines on Liquidity Risk Management Practices (Fund Management Companies) (LRM Guidelines), to provide greater clarity on MAS’ expectations on the management of liquidity risks by fund management companies (FMC).

    The proposals were issued pursuant to the International Organization of Securities Commissions (IOSCO) Final Report on Revised Recommendations for Liquidity Risk Management for Collective Investment Schemes issued in May 2025 and Financial Stability Board’s Final Report on Liquidity Preparedness for Margin and Collateral Calls issued in December 2024. As before, an FMC may apply the LRM Guidelines in a proportionate manner, taking into account the nature, size, and complexity of its activities.

    The key amendments proposed in the consultation paper:

    (a) Strengthening internal governance: An FMC should establish clear accountability and decision-making processes for the design and activation of liquidity management tools under both normal and stressed market conditions. The circumstances under which such tools may be activated should be set out, and the roles and responsibilities of decision makers should be defined. The board and senior management of an FMC should have adequate understanding of potential interactions between liquidity risk and other risk types.

    (b) Alignment between fund redemption terms and liquidity of fund assets: An FMC managing open-ended funds is expected to maintain consistency between the fund’s investment strategy and redemption terms under both normal and stressed market conditions. This alignment should be maintained both at the initial product design stage as well as on an ongoing basis.

    (c) Adoption of antidilution liquidity management tools (ADTs): An FMC is expected to adopt a diversified approach to liquidity management using both quantitative tools (e.g., suspension of redemptions and redemption gates) and ADTs (e.g., swing pricing). There should be provisions in place for at least one appropriate liquidity management tool, preferably ADTs, and reliance should not be placed solely on suspension or redemption gating. In the case of open-ended funds, particularly those that invest mainly in less-liquid assets, there should be at least one ADT implemented to mitigate material investor dilution.

    (d) Imposition of liquidity costs to transacting investors: To safeguard the interests of all investors, an FMC should implement measures such that investors who subscribe to or redeem from a fund bear the liquidity costs associated with their transactions. In particular, where ADTs have been activated, an FMC managing open-ended funds should impose both the explicit costs (e.g., brokerage fees and commissions, trading levies, and settlement fees) as well as implicit costs (e.g., bid-ask spread and market impact costs) on the subscribing or redeeming investors.

    (e) Enhancing investor disclosures: An FMC managing open-ended funds should disclose to investors (i) an overview of the fund’s investment strategy and potential liquidity risks, (ii) the features of the redemption terms (e.g., dealing frequency, lock-up periods, and notice and settlement periods), and (iii) the objective and circumstances under which liquidity management tools may be activated.

    (f) Ongoing liquidity risk management: An FMC should regularly monitor market depth, liquidity, and concentration of their portfolio positions so that liquidity risks arising from margin and collateral calls are adequately managed and mitigated. Regular reviews should be performed to assess the effectiveness of the liquidity management tools applied and whether additional tools are needed in the management of liquidity mismatches and to provide fair treatment of all investors, where relevant. There should be formalized processes to monitor early warning indicators of potential deterioration in a fund’s liquidity as well as escalation and reporting procedures. 

    (g) Removal of exchange-traded funds (ETFs) from the scope of the LRM Guidelines: This is pursuant to further guidance issued by IOSCO on ETFs, as ETFs have different liquidity considerations and structural features from open-ended funds.

    The consultation period closes on 28 February 2026. The revised LRM Guidelines are expected to come into effect six months after being finalized and published by the MAS. In the meantime, FMCs are encouraged to begin preparations as early as possible.

    REGULATORY STANDARDS/UPDATES

    SFC Exempts Non-Centrally-Cleared Equity Options From Over-the-Counter Margin Requirements

    December 2025: The SFC confirmed it will exempt non-centrally-cleared single-stock options, equity basket options, and equity index options from the over-the-counter (OTC) margin requirements with effect from January 4, 2026. This exemption, which will last until further notice, aims to align with global developments, specifically mirroring approaches in the EU and the UK, and is partly due to licensed corporations’ insignificant current exposure to these options. 

    MAS Sets Standards on Recruitment and Onboarding Training of Representatives

    December 2025: MAS issued an information paper setting out standards that it expects financial institutions to apply when assessing whether their appointed representatives are fit and proper to carry out regulated activities. The paper sets out MAS’s supervisory expectations in the following areas: (i) onboarding of representatives, (ii) monitoring of representatives with adverse information, (iii) onboarding training, and (iv) hiring of assistants by representatives and outsourced activities.

    MAS Revises Representative Misconduct Reporting Requirements

    December 2025: The new Notice SFA 04-N24 on Reporting of Misconduct of Representatives by Holders of Capital Markets Services Licence and Exempt Persons was issued by MAS after two rounds of public consultation. The new notice, which takes effect on January 1, 2027, revises the scope of reportable “misconduct” to mean (i) any act relating to a contravention of the market conduct provisions under Part 12 of the Singapore Securities and Futures Act 2001, or (ii) any act involving fraud, dishonesty, illegal monetary gains, or any offense of a similar nature (such as cheating, forgery, dishonest misappropriation of monies, criminal breach of trust, bribery, money laundering, and tax evasion). The reporting templates to be used by financial institutions for the misconduct report and investigation report is expected to be shared by MAS by Q2 2026.

    MAS Streamlines Incident Reporting Processes

    December 2025: MAS has streamlined its incident reporting template and submission channel to facilitate more standardized and streamlined incident data collection. The updates apply to incident reporting under various MAS-issued instruments, including the following notices and guidelines  as applicable to Singapore fund management companies: Notice on Technology Risk Management, Guidelines on Business Continuity Management and Guidelines on Outsourcing (Financial Institutions other than Banks). In the event of a reportable incident, financial institutions are to provide initial notification to MAS by contacting its MAS review officer (during office hours) or MAS duty officer (outside of office hours or if the MAS review officer is uncontactable). Following the initial notification, financial institutions are to submit all incident reports to MAS via MAS-Tx using the new incident reporting template from February 1, 2026, onward.

    SFC Refines List of Persons Designated as Financial Services Providers Under OTC Clearing Regime

    December 2025: The revised list of designated financial service providers (FSPs) under the OTC derivatives clearing regime became effective on January 1, 2026. Licensed persons (including significant nonfinancial counterparties) whose average total position in OTC derivatives meets the US$20 billion clearing threshold must ensure that relevant transaction with designated FSPs are centrally cleared. The list, which contains over 100 entities, primarily includes entities that are part of global systemically important bank groups or major dealer groups that are also clearing members of the largest central counterparties for interest rate swaps in major markets (U.S., Europe, Japan, and Hong Kong).

    Hong Kong to Standardize Calculation Periods Under OTC Clearing Regime

    January 2026: The SFC and HKMA have jointly proposed adopting two “Calculation Periods” annually for OTC derivatives clearing, effective March 1, 2027. These periods would run from March 1 to May 31 and September 1 to November 30 each year, aiming to enhance operational efficiency and certainty for derivative dealers by standardizing the process for identifying firms that meet the US$20 billion clearing threshold.

    INTERMEDIARIES/MARKET SUPERVISION

    SFC Enhances Regulatory Cooperation on Cross-Border Digital Asset–Related Matters

    January 2026: The SFC entered into an MOU with the Capital Markets Authority of the United Arab Emirates to enhance regulatory cooperation on the supervision of cross-border digital asset–related activities. The MOU establishes a framework for cooperation and exchange of information including, changes that potentially affect the financial or operational stability of regulated entities, for example, enforcement actions or sanctions, ownership changes, major cyberattacks, security breaches, or system failures.

    Reminder of Statutory Obligations During SFC Inspections

    January 2026: The SFC issued a stern reminder that Section 180 inspections are mandatory statutory obligations, not negotiable requests. The SFC is moving to eliminate the “friction” caused by firms’ using administrative or legal excuses to stall supervisory efforts. Common shields such as client confidentiality, staff absences, or data privacy are now explicitly deemed insufficient reasons to delay or withhold information. Beyond criminal liability for obstruction, the SFC warned of immediate supervisory interventions for noncooperation, including suspending the onboarding of new clients and restricting business activities. Ultimately, the manager-in-charge (MIC) for overall management oversight (supported by the MIC for compliance) will be held personally accountable for any attempts to impede the process.

    Hong Kong Regulators Tighten Grip on IPO Gatekeepers

    January 2026: The SFC is cracking down on IPO sponsors following a surge in “process-driven” listing applications and declining document quality. Regulators are targeting resource strain, specifically identifying principals overseeing six or more active deals as lacking adequate supervision capacity. 
    Sponsors must immediately report staff who haven’t passed HKSI Paper 16 and disclose principal workloads. “Concerned sponsors” face on-site thematic inspections and must submit signed rectification plans within three months. The SFC warns that persistent failures in due diligence or expert oversight will result in restricted business scopes or suspended applications to protect market integrity.

    KEY PRODUCT DEVELOPMENTS

    SFC Streamlines Measures for Authorized EU-Regulated Retail Funds

    November 2025: The SFC announced streamlined post-authorization measures for Undertakings for Collective Investment in Transferable Securities (UCITS) funds to align with home jurisdiction regulations and enhance Hong Kong’s position as an asset management hub. Key changes include removing the need for prior SFC approval for changes to depositories, investment delegates supervised by home regulators, and material changes in investment objectives.

    Hong Kong Regulators Outline Strategic Priorities for Green Finance

    January 2026: The Green and Sustainable Finance Cross-Agency Steering Group (co-chaired by the SFC and HKMA) outlined its three-year (2026–28) strategic priorities to consolidate and strengthen sustainability disclosure, sustainable finance markets, external engagement, and talent development while elevating the focus on transition. Key initiatives include developing best practices for transition plan disclosure through a pilot program and enhancing Hong Kong’s position as a leading sustainable financing hub in Asia.

    Boosting Liquidity: SFC Permits Affiliated Market Makers and VA Margin Trading

    February 2026: The SFC issued new guidance to enhance the liquidity of the regional virtual asset (VA) market. These initiatives include permitting licensed VA brokers to offer margin financing for Bitcoin (BTC) and Ether (ETH) and providing a framework for licensed platforms to offer perpetual contracts to professional investors. Additionally, affiliates of licensed platforms can now act as market makers. On February 13, 2026, the SFC granted a new virtual asset trading platform license to Victory Fintech (VDX), bringing the total number of licensed platforms to 12.

    SIGNIFICANT ENFORCEMENT ACTIONS

    We highlight below several noteworthy disciplinary and enforcement actions that may be of interest to MICs/responsible officers (ROs), licensed representatives, intermediaries, and others operating in the Hong Kong financial markets. 

    Market Misconduct

    November 2025: The SFC secured its first custodial sentence against a finfluencer for providing unlicensed investment advice through a paid Telegram chat. A request for bail pending appeal was denied.

    December 2025: The SFC secured the conviction and immediate eight-month custodial sentence against the wife of a listco chairman for false trading. The defendant had placed a series of bid orders at inflated prices for the listco shares through her own personal account in the final minutes before market close to create a false appearance of demand and alleviate pressure from margin calls on her husband’s account.

    December 2025: A former vice president of a share registrar company was given an immediate custodial sentence following his guilty plea for insider dealing. While handling proxy forms for a proposed privatization, the defendant learned that the necessary voting threshold would not be met and sold his shares, avoiding a loss of approximately US$37,000.

    January 2026: A retail trader was convicted of false trading, ordered to disgorge all profits and complete 220 hours community service following his guilty plea to “scaffolding” (i.e., repeatedly placing and canceling trading orders at progressively higher prices) and conducting wash trades (i.e., acting as both buyer and seller). 

    Conflicts of Interest

    February 2026: The SFC sanctioned an investment manager and two MICs for extensive fund management failures involving six closed-end Cayman subfunds (Segregated Portfolios). The firm was fined over US$1 million for (among others) failure to disclose and avoid conflicts relating to six high-interest bearing loans made by the investment manager and its director (as lenders) to the Segregated Portfolios (as borrowers). The SFC also banned the CEO/RO and MIC for overall management oversight for 14 months for approving the loans and its MIC for anti-money-laundering for 12 months for failing to adequately screen investors of the Segregated Portfolios (or their beneficial owners), including checking their politically exposed person status.

    Virtual Assets

    January 2026: The SFC reprimanded and fined an online brokerage firm over US$500,00 for allowing retail clients to trade VA products intended only for professional investors over a four-year period. In determining the penalty, the SFC noted the firm self-reported the breaches, voluntarily compensated affected clients, and ceased all regulated activities in Hong Kong. 

    Internal Controls

    November 2025: The SFC suspended an RO, a director, and a MIC for over three months for allowing the unauthorized sale and transfer of client assets totaling over US$3 million. The MIC had neglected her duties to protect client assets from theft or fraud by processing instructions from a bogus email address and ignoring red flags (including the rejected telegraphic transfers). The licensed corporation was separately reprimanded and fined over US$116,000 for its internal control failures.

    December 2025: The SFC reprimanded and fined a Swiss private bank over US$1.4 million for systemic internal control failures that included (among others) inadequate product due diligence for 322 bonds that meant customers did not receive sufficient information and warnings for certain complex products.

    Unauthorized Personal Trading

    January 2026: A former account executive was suspended for seven months for facilitating unauthorized personal trading by an external broker in a client’s account. The external broker was also suspended for 27 months for concealing from his employer his use of the client’s account (held in the name of his relative) for personal trading.

    Miscellaneous: Life Bans

    January 2026: A former licensed representative of a well-known bank was banned for life following her criminal conviction for theft of more than US$198,000. She had retained the ATM card and PIN to make unauthorized withdrawals from a client’s bank account.

    Continue Reading